EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)

Model scores of the 29,894 trials active now.

Model score 8% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 12% of the time (422 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: treatment ofthe treatmentwomensymptomsgad
  Phrases that lowered it: healthyto evaluateevaluate theadultefficacy
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: quadruple (lowers risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 15.4% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: 65 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 79.5% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 0 (lowers risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 7711 (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Keywords listed: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Dose-Response Safety Study of ENX-102 in Patients With GAD NCT06653296 · started 2024 · scored riskier than 16% of active trials completed
• Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325 NCT00807937 · started 2008 · scored riskier than 81% of active trials completed
• A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2) NCT00658372 · started 2008 · scored riskier than 13% of active trials terminated
• A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1) NCT00658008 · started 2008 · scored riskier than 14% of active trials terminated
• A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3) NCT00658762 · started 2008 · scored riskier than 14% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.